Claritas Pharmaceuticals, Inc.
CLAZF · OTC
9/30/2021 | 6/30/2021 | 3/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | -$2,340 |
| G&A Expenses | $420 | $455 | $159 | $348 |
| SG&A Expenses | $514 | $549 | $159 | $348 |
| Sales & Mktg Exp. | $94 | $94 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $514 | $549 | $159 | -$1,992 |
| Operating Income | -$514 | -$549 | -$159 | $1,992 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $695 | -$715 | -$2,618 | $2,090 |
| Pre-Tax Income | $181 | -$1,264 | -$2,777 | -$598 |
| Tax Expense | $0 | $0 | -$476 | $56 |
| Net Income | $181 | -$1,944 | -$2,301 | -$654 |
| % Margin | – | – | – | – |
| EPS | 0.005 | -0.058 | -0.084 | -0.024 |
| % Growth | 108.8% | 30.4% | -246.9% | – |
| EPS Diluted | 0.005 | -0.058 | -0.084 | -0.024 |
| Weighted Avg Shares Out | 35,411 | 33,406 | 27,526 | 27,109 |
| Weighted Avg Shares Out Dil | 35,411 | 33,406 | 27,526 | 27,109 |
| Supplemental Information | – | – | – | – |
| Interest Income | $709 | $0 | $39 | $0 |
| Interest Expense | $14 | $715 | $59 | $27 |
| Depreciation & Amortization | $514 | $549 | $159 | -$1,992 |
| EBITDA | $695 | $0 | -$2,718 | -$2,827 |
| % Margin | – | – | – | – |